This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Prié, S. Articles by Dupuis, J. Search for Related Content PubMed PubMed Citation Articles by Prié, S. Articles by Dupuis, J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB MONOCROTALINE NITRIC OXIDE Medline Plus Health Information Pulmonary Hypertension

(Circulation. 1998;97:2169-2174.)
© 1998 American Heart Association, Inc.

Basic Science Reports

Endothelin_A Receptor Blockade Improves Nitric Oxide–Mediated Vasodilation in Monocrotaline-Induced Pulmonary Hypertension

Stéphane Prié, PhD; Duncan J. Stewart, MD; ; Jocelyn Dupuis, MD, PhD

From the Departments of Medicine, Montreal Heart Institute (S.P., J.D.), Montreal, Quebec, and St Michael's Hospital (D.J.S.), Toronto, Ontario, Canada.

Correspondence to Dr J. Dupuis, Research Center, Montreal Heart Institute, 5000 Belanger St E, Montreal, Quebec, Canada H1T 1C8. E-mail dupuisj{at}icm.umontreal.ca

Background—Nitric oxide (NO) and endothelin (ET) have been implicated in the pathogenesis of pulmonary hypertension (PH). Chronic ET_A antagonist therapy reduces PH in monocrotaline (MCT)-treated rats. Interactions between the L-arginine–NO pathway and the ET system have been described. We therefore studied the effect of long-term treatment with an oral ET_A antagonist (LU 135252) on NO-related vasodilation in isolated lungs from control rats and rats with MCT-induced PH.

Methods and Results—Three weeks after MCT injection, PH was associated with an increase in right ventricular pressure (from 27.4±0.9 to 66.6±4.1 mm Hg) and a decrease in endothelium-independent vasodilation in response to sodium nitroprusside (10^-10 to 10^-5 mol/L E_max, from 11.1±0.9 to 2.7±0.3 mm Hg). Endothelium-dependent vasodilation in response to acetylcholine (10^-9 to 10^-4 mol/L) and the calcium ionophore A23187 (10^-9 to 10^-7 mol/L) remained unaffected. Treatment with LU 135252 did not significantly affect the endothelium-dependent and -independent vasodilations in control rats. However, in MCT-treated rats, LU 135252 therapy significantly reduced right ventricular pressure (39.7±2.1 mm Hg), potentiated acetylcholine-induced vasodilatation (E_max, from 1.6±0.2 to 3.7±0.4 mm Hg), and improved the responses to sodium nitroprusside (E_max, from 2.7±0.3 to 5.6±0.6 mm Hg). LU 135252 did not significantly alter the non–receptor-mediated endothelium-dependent vasodilation to A23187 or pulmonary constitutive NO synthase activity.

Conclusions—MCT PH is associated with a reduced smooth muscle responsiveness to NO but a maintained endothelium-dependent vasodilatory potency. Long-term ET_A antagonist therapy not only restores smooth muscle responsiveness to NO but also increases endothelium-dependent dilation in response to acetylcholine. This mechanism may contribute to the therapeutic benefit of ET_A antagonists in PH.

Key Words: endothelin • pulmonary heart disease • endothelium • drugs

This article has been cited by other articles:

				J. Dupuis and M. M. Hoeper Endothelin receptor antagonists in pulmonary arterial hypertension Eur. Respir. J., February 1, 2008; 31(2): 407 - 415. [Abstract] [Full Text] [PDF]

				M.-S. Tan, C.-Y. Chai, J.-R. Wu, J.-L. Yeh, I.-J. Chen, A.-L. Kwan, A. Y. Jeng, H.-Y. Yang, M.-H. Lee, and Z.-K. Dai Differential Change in Expression of Pulmonary ET-1 and eNOS in Rats After Chronic Left Ventricular Pressure Overload. Experimental Biology and Medicine, June 1, 2006; 231(6): 948 - 953. [Abstract] [Full Text] [PDF]

				M. Clozel, P. Hess, M. Rey, M. Iglarz, C. Binkert, and C. Qiu Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in rats. Experimental Biology and Medicine, June 1, 2006; 231(6): 967 - 973. [Abstract] [Full Text] [PDF]

				Y. Kakinuma, S. Honma, T. Morimoto, H. Maruyama, A. Yamazaki, T. Ishimitsu, and I. Yamaguchi Continuous Intravenous Administration of a Low Dose of Epoprostenol Greatly Decreased Serum Concentrations of Endothelin-1 in Primary Pulmonary Hypertension: A Case Report Angiology, September 1, 2005; 56(5): 641 - 645. [Abstract] [PDF]

				R. T. Schermuly, H. Yilmaz, H. A. Ghofrani, K. Woyda, S. Pullamsetti, A. Schulz, T. Gessler, R. Dumitrascu, N. Weissmann, F. Grimminger, et al. Inhaled Iloprost Reverses Vascular Remodeling in Chronic Experimental Pulmonary Hypertension Am. J. Respir. Crit. Care Med., August 1, 2005; 172(3): 358 - 363. [Abstract] [Full Text] [PDF]

				A. Migneault, S. Sauvageau, L. Villeneuve, E. Thorin, A. Fournier, N. Leblanc, and J. Dupuis Chronically Elevated Endothelin Levels Reduce Pulmonary Vascular Reactivity to Nitric Oxide Am. J. Respir. Crit. Care Med., March 1, 2005; 171(5): 506 - 513. [Abstract] [Full Text] [PDF]

				M. Ono, Y. Sawa, S. Mizuno, N. Fukushima, H. Ichikawa, K. Bessho, T. Nakamura, and H. Matsuda Hepatocyte Growth Factor Suppresses Vascular Medial Hyperplasia and Matrix Accumulation in Advanced Pulmonary Hypertension of Rats Circulation, November 2, 2004; 110(18): 2896 - 2902. [Abstract] [Full Text] [PDF]

				N. Galie, A. Manes, and A. Branzi The endothelin system in pulmonary arterial hypertension Cardiovasc Res, February 1, 2004; 61(2): 227 - 237. [Abstract] [Full Text] [PDF]

				S C Apostolopoulou, S Rammos, Z S Kyriakides, D J Webb, N R Johnston, D V Cokkinos, and D T. Kremastinos Acute endothelin A receptor antagonism improves pulmonary and systemic haemodynamics in patients with pulmonary arterial hypertension that is primary or autoimmune and related to congenital heart disease Heart, October 1, 2003; 89(10): 1221 - 1226. [Abstract] [Full Text] [PDF]

				F. Wiesmann, A. Frydrychowicz, J. Rautenberg, R. Illinger, E. Rommel, A. Haase, and S. Neubauer Analysis of right ventricular function in healthy mice and a murine model of heart failure by in vivo MRI Am J Physiol Heart Circ Physiol, September 1, 2002; 283(3): H1065 - H1071. [Abstract] [Full Text] [PDF]

				J. E. Jones, L. Mendes, M. A. Rudd, G. Russo, J. Loscalzo, and Y.-Y. Zhang Serial noninvasive assessment of progressive pulmonary hypertension in a rat model Am J Physiol Heart Circ Physiol, July 1, 2002; 283(1): H364 - H371. [Abstract] [Full Text] [PDF]

				J.-F. Jasmin, M. Lucas, P. Cernacek, and J. Dupuis Effectiveness of a Nonselective ETA/B and a Selective ETA Antagonist in Rats With Monocrotaline-Induced Pulmonary Hypertension Circulation, January 16, 2001; 103(2): 314 - 318. [Abstract] [Full Text] [PDF]

				B. Hocher, A. Schwarz, K. A. Fagan, C. Thöne-Reineke, K. El-Hag, H. Kusserow, S. Elitok, C. Bauer, H.-H. Neumayer, D. M. Rodman, et al. Pulmonary Fibrosis and Chronic Lung Inflammation in ET-1 Transgenic Mice Am. J. Respir. Cell Mol. Biol., July 1, 2000; 23(1): 19 - 26. [Abstract] [Full Text]

				C. Veyssier-Belot and P. Cacoub Role of endothelial and smooth muscle cells in the physiopathology and treatment management of pulmonary hypertension Cardiovasc Res, November 1, 1999; 44(2): 274 - 282. [Abstract] [Full Text] [PDF]

				B Prendergast, D E Newby, L E Wilson, D J Webb, and P S Mankad Early therapeutic experience with the endothelin antagonist BQ-123 in pulmonary hypertension after congenital heart surgery Heart, October 1, 1999; 82(4): 505 - 508. [Abstract] [Full Text] [PDF]

				A. Y. Saadjian, F. Paganelli, M. L. Reynaud Gaubert, S. Levy, and R. P. Guieu Adenosine plasma concentration in pulmonary hypertension Cardiovasc Res, July 1, 1999; 43(1): 228 - 236. [Abstract] [Full Text] [PDF]

				J. Dupuis and S. Prie The ETA-Receptor Antagonist LU 135252 Prevents the Progression of Established Pulmonary Hypertension Induced by Monocrotaline in Rats Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1999; 4(1): 33 - 39. [Abstract] [PDF]